Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence D Wagman

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Brachytherapy|October 17, 2017
A prospective phase I comparison of toxicity and cosmesis outcomes of single-fraction IORT and hypofractionated radiotherapy with IORT boost in early-stage breast cancerTanuja Bhandari, Wesley Babaran, Afshin Forouzannia, et al.
The American Surgeon|October 3, 2012
Intraoperative electron radiotherapy boost as a component of adjuvant radiation for breast cancer in the community settingAfshin Forouzannia, Jay K Harness, Michele M Carpenter, et al.
Cancer|January 27, 2010
Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United StatesAvo Artinyan, Brian Mailey, Nicelio Sanchez-Luege, et al.
Journal of the American College of Surgeons|November 1, 2005
Paint-only is equivalent to scrub-and-paint in preoperative preparation of abdominal surgery sitesJoshua D I Ellenhorn, David D Smith, Roderich E Schwarz, et al.
Brachytherapy|June 26, 2019
Recurrence rates for patients with early-stage breast cancer treated with IOERT at a community hospital per the ASTRO consensus statement for APBIVenita L Williams, Tanuja Bhandari, Lillian J Chen, et al.
Journal of Surgical Oncology|September 16, 2022
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximabLawrence D Wagman, David A Geller, Samuel A Jacobs, et al.
Annals of Surgical Oncology|July 22, 2025
Reduced Floxuridine Dose Limits Hepatobiliary Toxicity Without Negatively Impacting Survival After Resection of Colorectal Cancer Liver MetastasesKevin P Labadie, Darrell Fan, Dana A Dominguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10Laurence E McCahill, Greg Yothers, Saima Sharif, et al.
American Journal of Clinical Oncology|October 11, 2008
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium TrialY Yen, Dean W Lim, Vincent Chung, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Brachytherapy|October 17, 2017
A prospective phase I comparison of toxicity and cosmesis outcomes of single-fraction IORT and hypofractionated radiotherapy with IORT boost in early-stage breast cancerTanuja Bhandari, Wesley Babaran, Afshin Forouzannia, et al.
The American Surgeon|October 3, 2012
Intraoperative electron radiotherapy boost as a component of adjuvant radiation for breast cancer in the community settingAfshin Forouzannia, Jay K Harness, Michele M Carpenter, et al.
Cancer|January 27, 2010
Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United StatesAvo Artinyan, Brian Mailey, Nicelio Sanchez-Luege, et al.
Journal of the American College of Surgeons|November 1, 2005
Paint-only is equivalent to scrub-and-paint in preoperative preparation of abdominal surgery sitesJoshua D I Ellenhorn, David D Smith, Roderich E Schwarz, et al.
Brachytherapy|June 26, 2019
Recurrence rates for patients with early-stage breast cancer treated with IOERT at a community hospital per the ASTRO consensus statement for APBIVenita L Williams, Tanuja Bhandari, Lillian J Chen, et al.
Journal of Surgical Oncology|September 16, 2022
NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximabLawrence D Wagman, David A Geller, Samuel A Jacobs, et al.
Annals of Surgical Oncology|July 22, 2025
Reduced Floxuridine Dose Limits Hepatobiliary Toxicity Without Negatively Impacting Survival After Resection of Colorectal Cancer Liver MetastasesKevin P Labadie, Darrell Fan, Dana A Dominguez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10Laurence E McCahill, Greg Yothers, Saima Sharif, et al.
American Journal of Clinical Oncology|October 11, 2008
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium TrialY Yen, Dean W Lim, Vincent Chung, et al.
Pageof 4